Mechanism
Gastric emptying and tachyphylaxis
GLP-1 receptor agonists slow gastric emptying, especially early after dose escalation. With ongoing dosing the gastric-emptying effect diminishes (tachyphylaxis), while appetite suppression in the brain remains. This is why early GI side effects often improve over time even as weight reduction continues.
Plain-English explanation
GLP-1 receptor agonists slow gastric emptying, especially early after dose escalation. With ongoing dosing the gastric-emptying effect diminishes (tachyphylaxis), while appetite suppression in the brain remains. This is why early GI side effects often improve over time even as weight reduction continues.
Research-level explanation
Well-characterised in mechanistic and pharmacodynamic studies of liraglutide and semaglutide. Tachyphylaxis to gastric-emptying delay is one of the key reasons appetite-related and central effects are now thought to dominate chronic weight reduction.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Slowed stomach emptying explains all GLP-1 RA weight loss. | Chronic weight reduction is sustained even after gastric emptying tachyphylaxis develops, indicating central appetite and food-reward effects are the dominant contributors over months and years. |
Safety relevance
Gastric-emptying effects underlie the early dominant adverse-event profile (nausea, vomiting). Severe gastroparesis-like events have been reported and are subject to ongoing pharmacovigilance.
- Tachyphylaxis to one effect does not imply tachyphylaxis to all effects.
- Faster titration does not predict more weight reduction; it may simply produce more GI events.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site